226 related articles for article (PubMed ID: 17058739)
1. Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.
Kaufmann P; Dauphine CE; Vargas MP; Burla ML; Isaac NM; Gonzalez KD; Rosing D; Vargas HI
Am Surg; 2006 Oct; 72(10):935-8. PubMed ID: 17058739
[TBL] [Abstract][Full Text] [Related]
2. Breast conservation after induction chemotherapy for locally advanced breast cancer.
Kling KM; Ostrzega N; Schmit P
Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
4. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Denis F; Desbiez-Bourcier AV; Chapiron C; Arbion F; Body G; Brunereau L
Eur J Surg Oncol; 2004 Dec; 30(10):1069-76. PubMed ID: 15522553
[TBL] [Abstract][Full Text] [Related]
5. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial.
Loibl S; von Minckwitz G; Raab G; Blohmer JU; Dan Costa S; Gerber B; Eidtmann H; Petrich S; Hilfrich J; Jackisch C; du Bois A; Kaufmann M
Ann Surg Oncol; 2006 Nov; 13(11):1434-42. PubMed ID: 16983592
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
9. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
Mazouni C; Naveau A; Kane A; Dunant A; Garbay JR; Leymarie N; Sarfati B; Delaloge S; Rimareix F
Breast; 2013 Dec; 22(6):1189-93. PubMed ID: 24054903
[TBL] [Abstract][Full Text] [Related]
10. [Primary systemic therapy in breast cancer patients (2007-2010)].
Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
[TBL] [Abstract][Full Text] [Related]
11. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
Cooper BW; Radivoyevitch T; Overmoyer BA; Shenk RR; Pham HT; Samuels JR; Parry MP; Silverman P
Breast Cancer Res Treat; 2006 Jun; 97(3):311-8. PubMed ID: 16344915
[TBL] [Abstract][Full Text] [Related]
13. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
[TBL] [Abstract][Full Text] [Related]
14. Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients.
Wachter DL; Fasching PA; Haeberle L; Schulz-Wendtland R; Dimmler A; Koscheck T; Renner SP; Lux MP; Beckmann MW; Hartmann A; Rauh C; Schrauder MG
Arch Gynecol Obstet; 2013 Feb; 287(2):337-44. PubMed ID: 22955249
[TBL] [Abstract][Full Text] [Related]
15. Early experiences of breast-conservation treatment combined with tamoxifen and CAF chemotherapy for breast cancer of stages I and II.
Ogawa Y; Nishioka A; Inomata T; Hamada N; Terashima M; Yoshida S; Tanaka Y; Ogoshi S; Araki K; Kumon M
Radiat Med; 1994; 12(1):29-35. PubMed ID: 8016401
[TBL] [Abstract][Full Text] [Related]
16. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy in locally advanced breast cancer.
Singh G; Singh DP; Gupta D; Muralikrishna BV
J Surg Oncol; 1996 Jan; 61(1):38-41. PubMed ID: 8544458
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
19. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
[TBL] [Abstract][Full Text] [Related]
20. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
